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Previous studies have shown targeting different tissues via the transcutaneous (TC)
and intramuscular injection (IM) with or without electroporation (EP) has the potential
to trigger immune responses to DNA vaccination. The CUTHIVTHER 001 Phase I/II
randomized controlled clinical trial was designed to determine whether the mode of
DNA vaccination delivery (TC+IM or EP+IM) could influence the quality and function
of induced cellular immune responses compared to placebo, in an HIV positive clade B
cohort on antiretroviral therapy (ART). The GTU®MultiHIV B DNA vaccine DNA vaccine
encoded a MultiHIV B clade fusion protein to target the cellular response. Overall the
vaccine and regimens were safe and well-tolerated. There were robust pre-vaccination
IFN-γ responses with nomeasurable change following vaccination compared to placebo.
However, modest intracellular cytokine staining (ICS) responses were seen in the TC+IM
group. A high proportion of individuals demonstrated potent viral inhibition at baseline
that was not improved by vaccination. These results show that HIV positive subjects with
nadir CD4+ counts ≥250 on suppressive ART display potent levels of cellular immunity
and viral inhibition, and that DNA vaccination alone is insufficient to improve such
responses. These data suggest that more potent prime-boost vaccination strategies are
likely needed to improve pre-existing responses in similar HIV-1 cohorts (This study has
been registered at http://ClinicalTrials.gov under registration no. NCT02457689).
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INTRODUCTION
The development of safe and effective antiretroviral therapy
(ART) has led to almost near normal life expectancy in people
living with HIV, if diagnosed early and established on treatment
(1). However, ART whilst able to control infection cannot
eradicate the viral reservoir, as evidenced by viral rebound
after treatment interruption (2, 3). Additional approaches are
required to provide long-term remission from viral rebound
during treatment interruption.
The rationale for the development of a therapeutic HIV-
1 vaccine is based on several immunological factors. These
include the inability of natural infection with HIV to elicit
sufficient immunity to control replication, HIV infection itself
causing major abnormalities in the cellular immune response
and the failure of ART to eradicate established infection (4). A
successful therapeutic vaccine needs to induce a broad immune
response, modify the host immune response, and help eradicate
the reservoir (5). Several combination strategies are currently
in progress including the use of a vaccine plus latency reversal
agent known as the “shock and kill” approach (6, 7), gene therapy
with modification of CCR5 expression on target cells (8), and the
use of broadly neutralizing antibodies to induce ART-free viral
suppression (9).
The CUTHIVTHER 001 trial was a placebo controlled
randomized trial designed to explore the safety and
immunogenicity of 2 different delivery modes of the
GTU R©MultiHIV B DNA vaccine in HIV clade B positive
volunteers on established ART. Data from a previous study,
performed in South African clade C infected volunteers (not
on ART) using the same DNA vaccine showed that both
intramuscular (IM) and intradermal (ID) delivery was safe and
well-tolerated with no vaccine-related serious adverse events
(SAEs) (10). A modest but significantly lower log pHIV-RNA
was seen in subjects receiving vaccine compared to placebo
(p = 0.012) with a trend toward higher CD4+ T cell counts
(p = 0.066). These changes were more pronounced after IM
administration and in some HLA haplotypes (B∗5703) and
maintained for 17 months after the final immunization. Given
this clade B vaccine was not matched to the predominant clade
C epidemic in Sub-Saharan Africa, it is reasonable to expect it to
be more effective when tested in a clade matched cohort and that
this could be further enhanced using electroporation (EP).
More recent data from our previous clinical trial in
HIV negative volunteers (CUTHIVAC 001) demonstrated that
IM+EP delivery of the same vaccine promoted strong IFN-
γ responses with potent viral inhibition compared to standard
delivery by IM+ID (11). Only one other trial to date has used
IM+EP with DNA in the context of therapeutic vaccination and
showed enhanced CD4+ but not CD8+ T cell responses (12). By
contrast TC+IM (without EP) shifted responses toward a more
Th-17 dominated phenotype associated with mucosal protection.
In this respect, TC vaccination, mediated by targeted DNA
delivery via hair follicles following cyanoacrylate skin surface
stripping, represents a novel route of immunization. To the best
of our knowledge, this is the first trial using TC vaccination with
DNA in a HIV positive cohort.
MATERIALS AND METHODS
Trial Design
The CUTHIVTHER 001 was a Phase I/II randomized controlled
clinical trial to investigate the safety and immunogenicity of the
GTU R©MultiHIV B clade DNA vaccine administered 3 times in
people living with clade B HIV infection who were stable on
antiretroviral therapy (ART). This was defined as a viral load
of <50 copies/ml on 2 separate occasions in the last 6 months
prior to enrolment, nadir CD4 ≥ 250, and screening CD4 ≥200
(Supplementary Table 2.1). The vaccine was administered either
IM and enhanced with EP, or IM with TC delivery at 0, 4,
and 12 weeks (Supplementary Figure 2.1). A placebo group was
included in anticipation of high background responses to peptide
pools in a HIV-infected cohort of participants. Participants were
randomized to receive either IM+EP or IM+TC vaccination
with a further randomization to receive placebo (normal saline)
or vaccine. The primary safety endpoint was a grade 3 (severe)
local or systemic reaction or an adverse event that led to
a clinical decision to discontinue vaccination. The primary
immunogenicity endpoint was a doubling in IFN-γ ELISpot
response to any of the vaccine peptides between week 0 and
week 14.
Ethics
The CUTHIVTHER 001 trial was conducted in compliance
with UK Clinical Trial Regulations and within the principles
of Good Clinical Practice (GCP). The study was approved by
the National Research Ethics Service, York North East Research
Ethics Committee (4/NE/1246, Eudract 2013-004023-37) and by
the Medicines and Healthcare products Regulatory Authority
(MHRA). All participants provided written informed consent
after thorough counseling by the clinical trial team.
Intervention
The investigational GTU R©MultiHIV B clade DNA vaccine is a
synthetic fusion protein comprising of full-length polypeptides of
Rev, Nef, Tat, p17/p24, and CTL (containing epitopes of protease,
reverse transcriptase, and gp160) regions of the primary HAN-
2 HIV B clade virus. This vector developed by FIT Biotech
is a non-replicating expression vector with enhanced features
provided by the bovine papilloma virus transcriptional activators
and segregation/partitioning factor E2 protein along with its
multimeric specific sites (13).
Transcutaneous Vaccination
0.2ml (0.4mg) of DNA vaccine was administered by the TC route
on the external aspect of the upper left arm below the deltoid
muscle as previously described (11). In brief, a total amount of
190mg (equivalent to 9 drops) of cyanoacrylate glue was applied
over the investigational site (16 cm2), followed by the application
of adhesive tape. After hardening of the glue for 20min, the tape
and glue were removed from the skin surface. In order to prevent
uncontrolled spreading and loss of vaccine, a rectangular silicone
frame was then taped onto the investigational site. The vaccine
was then applied drop-wise and spread using a finger cot over the
investigational site. This application procedure was followed by
an incubation time of 20min after which a hydrocolloid bandage
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was placed over the arm for 24 h. TC application was followed
by IM injection of 1ml (2mg) of DNA vaccine into the vastus
lasteralis muscle as described below (Supplementary Data 1.1).
Intramuscular Injection With
Electroporation
1ml (2mg) of DNA vaccine was loaded into a disposable
electroporation cartridge and delivered IM followed by
electroporation using the same hand-held delivery system into
the vastus lasteralis muscle of the left leg (TriGrid Delivery
systems, San Diego, CA). This method has been described
previously (14) (Supplementary Data 1.2).
IFN-γ ELISpot Assay
IFN-γ ELISpot assays were performed using frozen isolated
peripheral blood mononuclear cells stimulated with peptide
pools (see Supplementary Table 2.9) matched to the
GTU R©MultiHIV B clade DNA vaccine using a technique
previously described (15). An additional integrase peptide pool
was added as a control to the assay as the presence of a peptide
pool not included in the vaccine may give information on
any non-specific changes occurring within T cells related to
vaccination (Supplementary Data 1.3). All samples were run
in triplicate.
Human Leucocyte Antigen (HLA) Typing
Blood was taken at week 0 and high and low resolution HLA
class I typing was performed by sequence specific PCR according
to standard protocols at the Department of Histocompatibility
and Immunogenetics, Hammersmith Hospital. The final HLA I
typing results is presented as “interpreted” HLA type combining
high and low resolution PCR.
Viral Inhibition Assay
This assay was based on a modified version of a previously
described assay (16).
In the endogenous Viral inhibition assay, CD4+ cells were not
infected with exogenous virus, but endogenous virus was allowed
to replicate during the cell expansion phase of the assay. The Viral
inhibition assay was conducted at (week 0) and post vaccination
(week 14) to determine whether endogenous virus was inhibited.
For the exogenous Viral inhibition assay, endogenous virus
was first blocked using the CCR5 inhibitor Maraviroc by adding
10µM to the culture on days 3 and 6. The Viral inhibition
assay was then conducted at pre (week 0) and post (week
14) vaccination time points as per previously described. Three
exogenous viruses were used in this part of the assay; IIIB (clade
B), U455 (clade A), and CBL4 (clade D) to determine clade
specific and cross clade activity (Supplementary Data 1.4). All
samples were run in quadruplicate.
Intracellular Cytokine Analysis
Intracellular cytokine staining (ICS) was performed on PBMC
isolated on pre-vaccination (week 0), 2 weeks post-third
vaccination (week 14), and 8 weeks post-third vaccination (week
20) with a panel for CD8+ and CD4+ antigen-specific responses.
Briefly, overlapping peptide pools matching the vaccine (Gag,
Nef, Rev, Tat and CTL) were incubated with PBMC for 6 h
before staining CD4+/CD8+ T cells for CD107a BUV395, IFN-γ
AF488, TNF-α PE-Cy7, IL-2 BV510, CD154 BV421, Granzyme B
AF647, and Perforin PE. PMA/Ionomycin and integrase peptide
pool were used as positive controls. Samples were fixed prior to
flow cytometry analysis on a Becton Dickinson Fortessa LSRII.
Single samples were run for each condition, all data was analyzed
using FlowJo and boolean gated to show polyfunctionality
(Supplementary Data 1.5).
Statistical Analysis
All clinical and routine laboratory data is included in the
safety and immunogenicity analysis. Safety data are analyzed as
intention to treat. For the immunogenicity analysis the primary
endpoint was defined as 2 weeks after the third and final vaccine
(week 14). The difference in magnitude of the IFN-γ response
between the groups at the specified time points including the
primary endpoint for each peptide was compared using an
unpaired non-parametric t test (Mann-Whitney test). Results
were considered statistically significant if the 2 tailed P value was
<0.05. For the analysis of the difference within each individual
group week 0 and week 14, a paired t test (Wilcoxon matched-
pairs signed rank test) was used where statistical significance was
set at p=<0.05.
RESULTS
GTU®MultiHIV B Clade DNA Vaccine Is
Safe and Well-Tolerated in HIV Positive
Adults When Delivered by TC+IM and
EP+IM Routes
In total 36 participants were screened, and 30 met the eligibility
criteria (Supplementary Table 2.1). All but 1 participant
completed the vaccination schedule. This participant was in the
EP+IM (active arm) and was diagnosed with acute hepatitis C
following the second vaccine, and subsequently did not receive
the final vaccine but remained in follow up and is included in all
analyses (Supplementary Figure 2.2).
All participants enrolled were male with a median age of 34
years. 90% were White and 83% in full time employment. The
median number of years since diagnosis of HIV was 3 years, and
participants had nadir CD4+ counts ≥250 (median 346; range
260–968 cells/mm3). To be enrolled in the study all participants
had to be on ART for at least 6 months, and the mean number
of years on ART was 2.18 years with a combination of regimens,
the most common of which was triple therapy with an NRTI plus
NNRTI (Supplementary Table 2.3).
Overall the GTU R©MultiHIV B clade DNA vaccine was well-
tolerated compared to placebo. There were no serious adverse
events and only one primary endpoint (the participant who
acquired hepatitis C). The majority (73) of 82 unsolicited adverse
events (AEs) were mild in nature with the remaining 9 graded
moderate (Supplementary Table 2.4). Of note 7 participants
in the TC+IM group developed hyper or hypopigmentation
(6 active;1 placebo), all of which had resolved by the end of
the study.
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FIGURE 1 | Analysis of IFN-γ responses by ELISpot: (A) Comparison of IFN-È ELISpot responses pre vaccination and at the primary endpoint for all participants (both
groups); (B) Comparison of IFN-È response from week 0 to week 14 with all peptide pools together for the EP+IM group (active); (C) Comparison of IFN-È response
from week 0 to week 14 with all peptide pools together for the TC+IM group (active) to all peptide pools. Statistical significance is set at p = <0.05 (Wilcoxon
matched-pairs signed t test). Each dot joined together by a line is an individual’s IFN-È response at week 0 and 14. (D) Scatter dot plot showing baseline IFN-È
response at week 0 (pre vaccination) by group. All units are in SFU/M PBMC with background (from negative/mock wells) subtracted. The red dotted line represents
(Continued)
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FIGURE 1 | the cut off of >55 SFU/M but participants also had to meet the second criteria to be a positive responder (>4 x baseline response if baseline response is
more than 0). Viral inhibition assay: (E) IFN-È ELISpot responses to Integrase peptide for both groups receiving active drug at week 0 and week 14. (F) Comparison of
viral inhibition (log10) between week 0 and week 14 in the TC+IM group (including placebo). (G) Comparison of viral inhibition between week 0 and week 14 in the
EP+IM group (including placebo). The red line represents the cut off for positive inhibition of >1.5 log10. Statistical significance set at p = < 0.05.
The EP tolerability data collected from participants after
each vaccination suggested no difference in pain scores in those
receiving active drug or placebo. All participants deemed the EP
procedure to be acceptable both in the context of HIV prevention
and treatment (Supplementary Table 2.5).
IFN-γ ELISpot: Participants Demonstrated
Robust Pre-vaccination IFN-γ Responses
That Were Not Improved at the Primary
Endpoint Either Between or Within Groups
A comparison of the mean IFN-γ response by ELISpot at week
0 and the primary endpoint at week 14 shows little variability
in SFU/M PBMC with no significant difference comparing data
from all groups at week 0 and week 14 (p= 0.7335). Furthermore,
a comparison of the IFN-γ response within each group at week
0 and week 14 showed no significant difference for any peptide
at the primary endpoint in either the EP+IM (active) group or
TC+IM (active) group (Figures 1A–C).
Variability of pre-vaccination responses (week 0) was noted in
this trial and has been documented in other HIV-1 therapeutic
vaccine trials (17). In particular, 24/30 (80%) participants had
responses to Nef, and 26/30 (87%) to Gag and 12/30 (40%) to
CTL peptide pools respectively, with some IFN-γ responses above
the “positive” cut-off of >55 SFU/M PBMC (Figure 1D and
Supplementary Table 2.6).
As stated in the methods section, the integrase peptide pool
was not part of the vaccine construct but was used in the ELISpot
assay for this trial to determine if the mechanism of vaccination
could trigger non-specific changes in immune function. Data
from week 0 to week 14 in participants receiving active drug
showed no difference in the magnitude of the IFN-γ response
to integrase, either for pooled group data or within the groups
at these time points. In addition, at week 14 there were also no
differences in magnitude comparing the groups (Figure 1E and
Supplementary Figure 2.6).
With respect to favorable HLA genotypes (HLA B∗27, B∗57,
B∗58:01, B∗81:01 and B∗51) (18), 8/30 (27%) participants
were found to have favorable HLA genotypes with 3 of these
participants showing some change in the magnitude of the IFN-
γ response from baseline. However, with so few responders
overall a favorable HLA genotype is unlikely to have made a
significant contribution in the context of this trial. There were
6 participants in the EP+IM group and 4 in the TC+IM group
who did not receive active vaccine. Of these 3 participants showed
an increase in the magnitude of the IFN-γ response at week
14. The implications of this are considered in the discussion
section (Supplementary Figure 2.7). Our data did not show
significant changes in CD4+ count in the group receiving active
vaccination compared to placebo, as shown in the FIT-06 clinical
trial (Supplementary Table 2.7).
Viral Inhibition Assay: A High Proportion of
Participants Were Shown to Inhibit Virus
Pre-vaccination but Few Showed
Variability at the Primary Endpoint
Only 5 participants had detectable endogenous virus (measure
by p24) at baseline (week 0). 4 of 5 were shown to inhibit
virus at week 0 with only 2 going on to show a change in
log10 inhibition at week 14 (Supplementary Table 2.8). In the
exogenous Viral inhibition assay 89% of participants inhibited
virus at baseline, most commonly with U455 (clade A). At week
14, the majority (96%) of participants were shown to inhibit at
least 1 virus (including in the placebo groups). However, there
was no significant difference in log10 inhibition either between
groups, or within groups comparing pre-vaccination (week 0) to
primary endpoint (week 14) (Figures 1F,G). In addition, there
was little change in the median breadth of viruses inhibited at
week 14 in any group (Supplementary Figure 2.9).
ICS: Significant Differences in Cytokine
Production Were Observed in the TC+IM
Group
The intracellular cytokine response detected in PBMC was
detected by flow cytometry measuring antigen specific responses
in both CD4+ and CD8+ T cells. Background levels of cytokine
responses were found to be elevated in HIV positive volunteers
compared to previous studies with HIV negative individuals. A
significant increase in cytokine production was shown at the
primary endpoint in the TC+IM group compared to the EP+IM
group. This was observed for Tat and Nef specific CD8+ TNF-
α response (P values of 0.0008 and 0.0052 respectively). IFN-γ
production was shown to have significantly increased in CD4+
T cells after stimulation to Gag and in CD8+ T cells after Nef
stimulation, with P values of 0.0014 and 0.0262 respectively
(Figure 2). However, there was no statistical difference between
TC+IM and the placebo control, this may reflect the smaller
sample size. However, there was no clear trend overall which may
be masked with the higher baseline levels of cytokines observed.
DISCUSSION
In this Phase I/II randomized controlled clinical trial we aimed
to determine whether the mode of DNA vaccination could
influence the quality and function of induced cellular immune
responses compared to placebo, in an HIV positive cohort on
ART. To the best of our knowledge this is the first human
study of DNA vaccination using TC mode of vaccine delivery in
people living with HIV. Overall, the vaccine was well-tolerated
using both modes of delivery with no SAEs reported in the
trial. In addition, despite reported pain associated with the EP
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FIGURE 2 | ICS analysis of T cell responses to DNA vaccination: (A) CD4+ IFN-È response at primary endpoint (week 14) for all groups to Gag; (B) CD4+ CD154
response at primary endpoint (week 14) for all groups to Rev; (C) CD8+ IFN-È response at primary endpoint (week 14) for all groups to Nef; (D) CD8+ TNF-α
response at primary endpoint (week 14) for all groups to Tat; and (E) CD8+ TNF-α response at primary endpoint (week 14) for all groups to Nef. Statistical significance
for all result is set at p = <0.05. *p < 0.05, **p <0.01, ***p<0.001.
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procedure, participants considered this an acceptable mode of
vaccine delivery as reported in previous clinical trials (11, 14).
In this cohort, participants were highly selected with nadir
CD4+ counts ≥ 250 and undetectable viral loads. It is not
entirely surprising to observe no change in response by IFN-
γ. In addition, the variability of responses in the placebo
group suggests that defining a “positive” response of >2-fold
increase was too low. The presence of changes in response
from baseline in placebo recipients could reflect the variability
of background response to peptide pools in an HIV positive
cohort, but could also be attributed to the actual procedures
themselves (electroporation and transcutaneous skin surface
stripping) creating inflammation and activating cells in the
absence of active drug. The observation of similar changes in the
placebo group suggests changes in the active groups are likely
non-specific and not related to active vaccination.
With respect to the integrase peptide pool, with so few
responders it is unlikely that vaccination has resulted in non-
specific immune changes in either group at the primary endpoint.
The presence of responders to this peptide pool in placebo
recipients raises similar questions of background variation or
inflammation created by the vaccination process.
To the best of our knowledge, this was the first trial using
the transcutaneous route in combination with IM injection for
DNA vaccination in an HIV positive cohort. In a previous
trial using the same TC vaccine administration route, 6 HIV
positive participants were vaccinated with Tetragrip (combined
tetanus and influenza vaccine) and compared to the same vaccine
delivered IM to 8 HIV positive patients. In the HIV positive
volunteers receiving TC vaccination, there was a preferential
amplification of vaccine-specific CD8+ cells (shown by ICS),
with the authors concluding the results demonstrated this route
of vaccination could affect the quality of the T cell response, albeit
in small participant numbers (19).
In our previous CUTHIVAC 001 trial in HIV negative
subjects, a comparison of week 0 and week 14 ICS responses
within each group also showed a predominantly CD8+ response
in the TC+IM group, specifically to IFN-γ, IL-2, and CD154 (11).
However, these endpoint responses were of similar magnitude to
pre-existing responses observed at baseline in our HIV cohort.
These high baseline responses may have masked any effects of
the vaccine in this current study.
As stated previously it is not possible to make direct
comparisons on change in viral load in this trial with the FIT-06
clinical trial in South African infected clade C participants not on
ART, as all participants in CUTHIVTHER were on suppressive
ART. However, changes in CD4+ counts seen in FIT-06 were
not replicated in this trial. One factor to consider here is this
cohort had been established on effective ART, therefore may
already have achieved effective restoration or near-restoration of
immune function.
Only 5 participants had detectable endogenous virus
production in the endogenous Viral inhibition assay. These
data suggest for the majority of participants in this cohort of
healthy HIV positive people on suppressive ART, the frequency
of HIV positive cells that can be re-activated in culture is
below the limit of detection. Nevertheless, 4/5 participants
with endogenous virus displayed sufficient functioning CD8+
mediated immune responses to control in vitro viral replication
even prior to vaccination.
In the exogenous Viral inhibition assay assessing the ability
of CD8+ cells to inhibit exogenous virus, participants in each
group were able to inhibit the panel of viruses at week 0 further
supporting preservation of immune responses and specifically,
CD8+ function. There was little change post vaccination in the
ability to inhibit virus in any group, but participants shown to
inhibit virus at week 14 also included placebo recipients. The
modification of this assay needs further verification but could be
a starting point for using the Viral inhibition assay in an HIV
infected cohort.
Encouragingly these data show that HIV positive subjects
with good nadir CD4+ counts and undetectable viral loads
display potent CD8+ responses to HIV and functional viral
inhibition in an ex-vivo assay. Neither IM DNA delivery
with electroporation or transcutaneous immunization had a
detectable impact on these high pre-vaccination responses, as
measured by IFN-γ and ICS. Similarly, we were unable to detect
an improvement in viral inhibition in the Viral inhibition assay
suggesting that in this healthy HIV positive cohort on ART,
CD8+ function remains relatively preserved. Nevertheless, the
vaccine proved to be safe and tolerable. The inability to detect
any beneficial response over and above the high levels of pre-
existing immunity in this cohort does not mean the vaccine
was inactive. Indeed, ICS analysis detected statistical differences
between the TC+IM group and the EP+IM group but was
underpowered to see any difference with the placebo matched
control group. Future studies will be needed to determine
whether DNA vaccination by either route can serve as an effective
prime when combined with a boosting strategy including the use
of viral vectors such as MVA (20). Additional benefit may be
gained through strategies designed to refocus responses beneficial
T-cell responses toward subdominant conserved regions of
HIV-1 (21).
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